Tego Science. Inc.

As of June 30, 2026, Tego Science. Inc. carries a market capitalization of 55.33B, placing it among publicly traded companies globally. Its enterprise value stands at 28.00B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Tego Science. Inc. has 8.01M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 8.95, and the price-to-book ratio stands at 1.27.

These figures are as of June 30, 2026. The EV/Sales ratio of 4.53 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 28.00B versus a market cap of 55.33B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Tego Science. Inc. maintains a current ratio of 1.64, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 42.12, indicating elevated leverage, while an interest coverage ratio of -2.59 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Tego Science. Inc. posted a negative return on equity (ROE) of -25.28, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -16.24, reflecting losses generated across the asset base. The company generates approximately 155.50M in revenue per employee across its workforce of 39.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.88 indicates how many times Tego Science. Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Tego Science. Inc. recorded an income tax benefit of -2.22B rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -15.14B and -12.91B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Tego Science. Inc.'s stock has declined approximately 59.65% over the past 52 weeks. The 50-day moving average sits at 7,367.20, while the 200-day moving average is 10,256.80.

Over the twelve months ended June 30, 2026, Tego Science. Inc. generated 6.18B in revenue and converted that into -12.91B in net income, yielding earnings per share of -1,613.42. EBITDA reached -5.53B, while operating income came in at -6.09B.

As of June 30, 2026, Tego Science. Inc. holds 45.67B in cash and equivalents against 18.36B in total debt, resulting in a net debt position of 12.36B. Total book value stands at 43.61B, with working capital of 20.86B providing operational flexibility.

Tego Science. Inc. produced -5.95B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -561.36M in capital expenditures, free cash flow totaled -6.51B - equivalent to -812.63 per share.

Over the twelve months ended June 30, 2026, Tego Science. Inc. posted a gross margin of 65.77, reflecting its pricing power and cost economics. The operating margin of -98.54 and net profit margin of -208.94 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -11.76: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.93, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Tego Science. Inc. shareholders.

Tego Science. Inc.'s most recent stock split took place on July 11, 2018 with a 1:2 split ratio.

As of June 30, 2026, Tego Science. Inc. has an Altman Z-Score of 1.05, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.